{"id":"W3025062498","doi":"10.1016/j.euo.2020.04.005","title":"Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study","year":2020,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Merck","keywords":"Fibroblast growth factor receptor 3; Bladder cancer; Medicine; Fibroblast growth factor receptor 4; Cancer research; Oncology; Pathological; Fibroblast growth factor receptor 2; Fibroblast growth factor receptor; Cancer; Internal medicine; Biology; Receptor; Fibroblast growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004240699,0.0003295653,0.001572492,0.0006272786,0.0002536514,0.001504877,0.0006692867,0.0005958322,0.001151854],"category_scores_gemma":[0.006479002,0.0002610073,0.001803129,0.001827366,0.0002660704,0.001856145,0.0006744906,0.00110256,0.0003069724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007068086,"about_ca_system_score_gemma":0.001402911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003025599,"about_ca_topic_score_gemma":0.01183598,"domain_scores_codex":[0.9985119,0.0004309617,0.0003380699,0.0001946912,0.0003959209,0.00012851],"domain_scores_gemma":[0.9962115,0.001625993,0.0009745621,0.0002176021,0.0007579477,0.0002124685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.007718244,0.0001194554,0.4244852,0.00659777,0.008580944,0.0004648479,0.0003566363,0.001673188,0.002114994,0.001022959,0.02629309,0.5205725],"study_design_scores_gemma":[0.0009266482,0.0008615468,0.872702,0.004360404,0.01750753,0.001514833,0.0009185849,0.001061309,0.0007617102,0.001905694,0.09735716,0.0001225404],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.4543579,0.4848901,0.003464142,0.02146557,0.001542356,0.0002490399,0.01826092,0.0000981429,0.01567187],"genre_scores_gemma":[0.8584039,0.1013612,0.003540636,0.01188349,0.001408909,0.0002115367,0.02193465,0.00008945672,0.001166109],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004240699,"threshold_uncertainty_score":0.02242726,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03695168064423887,"score_gpt":0.2950758822271127,"score_spread":0.2581242015828739,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}